Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
1. A method for treatment of lung fibrosis in a subject, wherein the method comprises administering an effective amount of 4-(((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl-)amino)methyl)-N-(pyridin-4-yl)benzamide, having the following formula
or a pharmaceutically acceptable salt, solvate or prodrug thereof as an active ingredient to the subject.
2. The method of claim 1 , wherein the effective amount of the active ingredient ranges from about 1.5 mg/kg/day to about 20 mg/kg/day.
3. The method of claim 1 , wherein the effective amount for treatment is about 5.0 mg/kg/day to about 15 mg/kg/day.
4. The method of claim 1 , wherein the effective amount for treatment is about 1.5 mg/kg/day to about 8 mg/kg/day.
5. The method of claim 1 , wherein the active ingredient is further co-administered with a second anti-fibrosis agent.
6. The method of claim 5 , wherein the second anti-fibrosis agent is pirfenidone, nintedanib, LOXL2 antibody, simtuzumab, IL-13 antibody, lebrikizumab, αVβ6 antibody, STX-100, CTGF antibody, FG-3019, tipelukast, MN-001, aerosol pirfenidone or GP-101.
7. The method of claim 5 , wherein the co-administration is simultaneous, separate or sequential administration.
8. The method of claim 1 , wherein the lung fibrosis is idiopathic pulmonary fibrosis.
9. The method of claim 1 , wherein the treatment of lung fibrosis further comprises a co-administered therapy with lung transplantation, hyperbaric oxygen therapy (HBOT) or pulmonary rehabilitation.